AU2017205320B2 - Fused quadracyclic compounds, compositions and uses thereof - Google Patents

Fused quadracyclic compounds, compositions and uses thereof Download PDF

Info

Publication number
AU2017205320B2
AU2017205320B2 AU2017205320A AU2017205320A AU2017205320B2 AU 2017205320 B2 AU2017205320 B2 AU 2017205320B2 AU 2017205320 A AU2017205320 A AU 2017205320A AU 2017205320 A AU2017205320 A AU 2017205320A AU 2017205320 B2 AU2017205320 B2 AU 2017205320B2
Authority
AU
Australia
Prior art keywords
esi
methanol
compound
optionally substituted
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017205320A
Other languages
English (en)
Other versions
AU2017205320A1 (en
Inventor
Casey Cameron Mccomas
Michael H. Serrano-Wu
Joseph P. Vacca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tabomedex Biosciences Inc
Original Assignee
Tabomedex Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tabomedex Biosciences Inc filed Critical Tabomedex Biosciences Inc
Publication of AU2017205320A1 publication Critical patent/AU2017205320A1/en
Assigned to Tabomedex Biosciences, Inc. reassignment Tabomedex Biosciences, Inc. Request for Assignment Assignors: Tabomedex Biosciences, LLC
Application granted granted Critical
Publication of AU2017205320B2 publication Critical patent/AU2017205320B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017205320A 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof Active AU2017205320B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662274640P 2016-01-04 2016-01-04
US62/274,640 2016-01-04
PCT/US2017/012092 WO2017120164A1 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2017205320A1 AU2017205320A1 (en) 2018-07-05
AU2017205320B2 true AU2017205320B2 (en) 2021-06-24

Family

ID=59226993

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017205320A Active AU2017205320B2 (en) 2016-01-04 2017-01-04 Fused quadracyclic compounds, compositions and uses thereof

Country Status (9)

Country Link
US (2) US10059718B2 (enExample)
EP (1) EP3400228B1 (enExample)
JP (1) JP7068185B2 (enExample)
CN (1) CN108779123B (enExample)
AU (1) AU2017205320B2 (enExample)
CA (1) CA3010213A1 (enExample)
ES (1) ES2915901T3 (enExample)
TW (1) TWI730027B (enExample)
WO (1) WO2017120164A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof
CN107879989B (zh) * 2017-11-29 2020-01-03 重庆市中药研究院 具有生物活性的3,4,5-取代苯并二氮卓2-酮类药物分子及其制备方法
CN118574834A (zh) * 2021-01-11 2024-08-30 泰博生物科技股份有限公司 稠合的四环化合物、其组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) * 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596799A (en) 1985-01-29 1986-06-24 Ciba-Geigy Corporation 9H-pyrrolo[2,1-c]-1,2,4-triazolo[4,3-a][1,4]benzodiazepines
TWI239333B (en) 2000-11-16 2005-09-11 Hoffmann La Roche Benzodiazepine derivatives as GABA A receptor modulators
AU2003301226A1 (en) 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
KR20150133172A (ko) 2013-03-15 2015-11-27 셀진 아빌로믹스 리서치, 인코포레이티드 Mk2 억제제 및 이의 용도
WO2014146164A1 (en) * 2013-03-22 2014-09-25 Lifi Labs Inc Color selection
US10059718B2 (en) 2016-01-04 2018-08-28 Tabomedex Biosciences, LLC Fused quadracyclic compounds, compositions and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521534A (en) * 1983-12-19 1985-06-04 Ayerst, Mckenna & Harrison, Ltd. Imidazo[2,1-a]pyrrolo[2,1-c][1,4]benzodiazepine derivatives, methods of preparation and use

Also Published As

Publication number Publication date
EP3400228B1 (en) 2022-04-13
ES2915901T3 (es) 2022-06-27
JP2019501971A (ja) 2019-01-24
JP7068185B2 (ja) 2022-05-16
EP3400228A1 (en) 2018-11-14
CA3010213A1 (en) 2017-07-13
US20180319809A1 (en) 2018-11-08
EP3400228A4 (en) 2019-08-14
US10059718B2 (en) 2018-08-28
AU2017205320A1 (en) 2018-07-05
CN108779123A (zh) 2018-11-09
WO2017120164A1 (en) 2017-07-13
US10562909B2 (en) 2020-02-18
US20170190713A1 (en) 2017-07-06
CN108779123B (zh) 2025-08-19
TW201726681A (zh) 2017-08-01
TWI730027B (zh) 2021-06-11

Similar Documents

Publication Publication Date Title
AU2020203035B2 (en) CDK Inhibitors
CA3107411C (en) Heterobicyclic compounds for inhibiting the activity of shp2
US10258626B2 (en) Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
AU2017346516B2 (en) Piperidine derivatives as inhibitors of ubiquitin specific protease 7
KR102638151B1 (ko) 키나아제 억제제 및 이의 용도
AU2015359624B2 (en) Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
RU2607371C1 (ru) Замещенные N2-(4-амино-2-метоксифенил)-N4-[2-(диметилфосфорил)-фенил]-5-хлор-пиримидин-2,4-диамины в качестве модуляторов ALK и EGFR, предназначенные для лечения рака
SK16812002A3 (sk) Látky na báze diazabicyklických zlúčenín ako prostriedky účinné na centrálny nervový systém
PT2989106T (pt) Compostos heterocíclicos fundidos como inibidores da proteína quinase
EA039714B1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
AU2017205320B2 (en) Fused quadracyclic compounds, compositions and uses thereof
AU2018339722B2 (en) Compound having ERK kinase inhibitory activity and use thereof
CA3195035A1 (en) Covalent egfr inhibitors and methods of use thereof
WO2025210407A1 (en) (7-{1h,2h,3h-pyrido [2,3-b][1,4]oxazin-7-yl}-5h,6h,7h,8h-pyrido[3,4-d]pyrimidin-2-yl)amine derivatives as bifunctional degraders of hpk1 for the treatment of cancer
HK40006173B (zh) 稠合四环化合物、其组合物和用途
HK40006173A (en) Fused quadracyclic compounds, compositions and uses thereof
HK1195067B (en) Cdk inhibitors

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TABOMEDEX BIOSCIENCES, INC.

Free format text: FORMER APPLICANT(S): TABOMEDEX BIOSCIENCES, LLC

FGA Letters patent sealed or granted (standard patent)